Abbott Labs Still Expects TriLipix Approval in 4Q08
Source: http://feeds.feedburner.com/~r/etfi/~3/430764130/abbott-labs-still-expects-trilipix.htmlPosted on Friday, October 24th, 2008 | In Exchange Traded Funds
Contributed by: ETF Innovators (http://etfinnovators.com) -
Abbott Labs Still Expects TriLipix Approval in 4Q08
Despite an unknown delay from the FDA on TriLipix, Abbott Labs (ABT) still expects approval before year-end. Other updates include a three month delay for Hologic (HOLX) and KV Pharma (KV-A) for Gestiva and a NDA filing yesterday for NeurogesX (NGSX) for its capsaicin skin patch (NGX-4010) in the treatment of post-herpetic neuralgia (nerve pain following shingles infection).
Last 5 posts by ETF Innovators
- Upcoming FDA Advisory Panel Meetings - March 9th, 2009
- Healthcare Investing Trends for '09 and Beyond - February 6th, 2009
- ThermoGenesis: A Stealth Stem Cell Play - January 31st, 2009
- President Obama Urges Greener Vehicles - January 26th, 2009
- Trading the Exchanges: Buying CME Group - December 26th, 2008
I am a pharmacist, freelance writer, and index developer for ETF Innovators, LLP, which creates new global equity indexes for licensing and commercialization as exchange-traded funds. I have been investing since August 1997 and freelance writing for investors since April 2007 with a focus on the healthcare sector and ETFs. I hold Doctor of Pharmacy (2003) and Bachelor of Science – Biology Major (1998) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. I am also an avid runner since 1992 and have completed 18 marathons (26.2 miles) with a personal best time of 2 hours, 54 minutes. I can be contacted by email at mikehav[at]ymail[dot]com.
My LinkedIn Profile: 
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.